Eva-Maria König

Dr. Eva-Maria König


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
NGNina Geiger
Nina Geiger
EKEva-Maria König
Eva-Maria König
HOHeike Oberwinkler
Heike Oberwinkler
VRValeria Roll
Valeria Roll
VDViktoria Diesendorf
Viktoria Diesendorf
JBJochen Bodem
Jochen Bodem
Aspirin, with its active compound acetylsalicylic acid (ASA), shows antiviral activity against rhino- and influenza viruses at high concentrations. We sought to investigate whether ASA and its metabolite salicylic acid (SA) inhibit SARS-CoV-2 since it might use similar pathways to influenza viruses. The compound-treated cells were infected with SARS-CoV-2. Viral replication was analysed by RTqPCR. The compounds suppressed SARS-CoV-2 replication in cell culture cells and a patient-near replication system using human precision-cut lung slices by two orders of magnitude. While the compounds did not interfere with viral entry, it led to lower viral RNA expression after 24 h, indicating that post-entry pathways were inhibited by the compounds.

15 August 2022 in Cells
Verified
Journal Article
Open access
PDF file
NGNina Geiger
Nina Geiger
LKLouise Kersting
Louise Kersting
JSJan Schlegel
Jan Schlegel
LSLinda Stelz
Linda Stelz
SFSofie Fähr
Sofie Fähr
JBJochen Bodem
Jochen Bodem
SARS-CoV-2 variants such as the delta or omicron variants, with higher transmission rates, accelerated the global COVID-19 pandemic. Thus, novel therapeutic strategies need to be deployed. The inhibition of acid sphingomyelinase (ASM), interfering with viral entry by fluoxetine was reported. Here, we described the acid ceramidase as an additional target of fluoxetine. To discover these effects, we synthesized an ASM-independent fluoxetine derivative, AKS466. High-resolution SARS-CoV-2–RNA FISH and RTqPCR analyses demonstrate that AKS466 down-regulates viral gene expression. It is shown that SARS-CoV-2 deacidifies the lysosomal pH using the ORF3 protein. However, treatment with AKS488 or fluoxetine lowers the lysosomal pH. Our biochemical results show that AKS466 localizes to the endo-lysosomal replication compartments of infected cells, and demonstrate the enrichment of the viral genomic, minus-stranded RNA and mRNAs there. Both fluoxetine and AKS466 inhibit the acid ceramidase activity, cause endo-lysosomal ceramide elevation, and interfere with viral replication. Furthermore, Ceranib-2, a specific acid ceramidase inhibitor, reduces SARS-CoV-2 replication and, most importantly, the exogenous supplementation of C6-ceramide interferes with viral replication. These results support the hypotheses that the acid ceramidase is a SARS-CoV-2 host factor.

Verified
Journal Article
Open access
PDF file
NGNina Geiger
Nina Geiger
VDViktoria Diesendorf
Viktoria Diesendorf
VRValeria Roll
Valeria Roll
EKEva-Maria König
Eva-Maria König
HOHelena Obernolte
Helena Obernolte
JBJochen Bodem
Jochen Bodem
Recently, we have described novel pyridyl indole esters and peptidomimetics as potent inhibitors of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) main protease. Here, we analysed the impact of these compounds on viral replication. It has been shown that some antivirals against SARS-CoV-2 act in a cell line-specific way. Thus, the compounds were tested in Vero, Huh-7, and Calu-3 cells. We showed that the protease inhibitors at 30 µM suppress viral replication by up to 5 orders of magnitude in Huh-7 cells, while in Calu-3 cells, suppression by 2 orders of magnitude was achieved. Three pyridin-3-yl indole-carboxylates inhibited viral replication in all cell lines, indicating that they might repress viral replication in human tissue as well. Thus, we investigated three compounds in human precision-cut lung slices and observed donor-dependent antiviral activity in this patient-near system. Our results provide evidence that even direct-acting antivirals may act in a cell line-specific manner.

29 August 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
CLCaroline Lekszas
Caroline Lekszas
OFOmbretta Foresti
Ombretta Foresti
IRIshier Raote
Ishier Raote
DLDaniel Liedtke
Daniel Liedtke
EKEva-Maria König
Eva-Maria König
THThomas Haaf
Thomas Haaf
The transport and Golgi organization 1 (TANGO1) family proteins have been shown to play pivotal roles in the secretory pathway. Full length TANGO1 is a transmembrane protein localised at endoplasmic reticulum exit sites (ERES), where it binds bulky cargo within the ER lumen and recruits membranes from the ER Golgi intermediate compartment (ERGIC) to create an exit route for their export. Tango1 knockout mice display a global collagen secretion defect and perinatal lethality. Here we report the first TANGO1-associated syndrome in humans, which mainly manifests in a collagenopathy. A synonymous substitution that results in exon 8 skipping in most mRNA molecules, ultimately leading to a truncated TANGO1 protein was identified as the disease-causing mutation. The four homozygously affected sons of a consanguineous family display severe dentinogenesis imperfecta, short stature, various skeletal abnormalities, insulin-dependent diabetes mellitus, sensorineural hearing loss, and mild intellectual disability. Functional studies in HeLa and U2OS cells revealed that the corresponding truncated TANGO1 protein is dispersed in the ER and its expression in cells with intact endogenous TANGO1 impairs cellular collagen I secretion.